Table 2—

Haemodynamics for the placebo/epoprostenol and bosentan/epoprostenol groups at baseline and week 16 (intent-to-treat population)

Haemodynamic parameterPlacebo/epoprostenolBosentan/epoprostenolp-value
BaselineWeek 16% changeBaselineWeek 16% change
TPR dyn·s−1cm51628±1541242±153−22.6±6.21697±1421016±78−36.3±4.30.08
CI L·min−1m21.7±0.22.3±0.237.9±13.31.7±0.12.5±0.148.7±11.00.6
PVR dyn·s−1cm51426±1401050±154−25.7±7.21511±129947±104−35.2±5.40.3
mPAP mmHg60.9±2.959.2±3.2−2.2±3.659.2±4.052.5±2.4−9.0±6.00.3
mRAP mmHg11.9±2.212.2±1.80.3±1.3#11.9±1.110.0±1.2−1.9±1.4#0.7
  • Data are presented as mean±sem

  • TPR: total pulmonary resistance

  • CI: cardiac index

  • PVR: pulmonary vascular resistance

  • mPAP: mean pulmonary artery pressure

  • mRAP: mean right atrial pressure

  • Note: the two bosentan patients who died and the two patients (one bosentan and one placebo) who were withdrawn were assigned the worst value observed at the 16 week time point or at withdrawal in all patients belonging to the same analysis population

  • #: absolute change in mRAP

  • changes in mRAP are more meaningful when expressed as absolute changes rather than per cent changes because of the small absolute values and the large variation in the per cent changes due to the substitution rules

  • : one placebo/epoprostenol and two bosentan/epoprostenol patients did not have a PVR calculation because of missing pulmonary artery wedge pressure

  • n=11 (placebo/epoprostenol) and 22 (bosentan/epoprostenol)